Mechanisms of Protein Seeding in Neurodegenerative Diseases
Open accessAbstract
Most age-associated neurodegenerative diseases involve the aggregation of specific proteins within the nervous system. In Alzheimer disease, the insidious pathogenic process begins many years before the symptoms emerge, and the lesions that characterize the disease—senile plaques and neurofibrillary tangles—ramify systematically through the brain. We review evidence that the -amyloid and tau proteins, which aggregate to form senile plaques and neurofibrillary tangles, respectively, are induced to misfold and self-assemble by a process of templated conformational change that amplifies a toxic species. Recent data also indicate that the spread of these lesions from one site to another is mediated by the cellular uptake, transport, and release of endogenous seeds formed by the cognate proteins. This simple pathogenic principle suggests that the formation, trafficking, and metabolism of pathogenic protein seeds are promising therapeutic targets for Alzheimer disease and other neurodegenerative disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antibodies, including anti-tau antibodies, can enter neurons.
“However, several groups have reported that antibodies, including anti-tau antibodies, can enter neurons, and that extracellular tau might be important for the spread of tau pathology227–229.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [228]
Extracellular tau might be important for the spread of tau pathology.
“However, several groups have reported that antibodies, including anti-tau antibodies, can enter neurons, and that extracellular tau might be important for the spread of tau pathology227–229.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [228]
In animal models that express tau only in certain brain regions, or that are injected with exogenous tau, spreading of tau pathology to anatomically connected regions occurs over time.
“In animal models that express tau only in certain brain regions, or that are injected with exogenous tau, spreading of tau pathology to anatomically connected regions occurs over time54,64,228.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 35 · Cited by 226
- Authors
- Walker, L. C., Diamond, M. I., Duff, K. E., & Hyman, B. T.
- Affiliations
- Emory University (US)
- Corresponding author
- Walker, Lary C.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-03-01
- Volume
- 70
- Issue
- 3
- Pages
- 304
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC3665718
- OpenAlex
- W1971487740
- Cited by
- 226
- References
- 35
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 17 · 2020: 14 · 2019: 13 · 2018: 19 · 2017: 15 · 2016: 27 · 2015: 31 · 2014: 27 · 2013: 20
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- American Health Assistance Foundation
- Muscular Dystrophy Association
- National Institutes of Health (P51OD011132)
- National Institute on Aging (R01AG026249, P01AG005119, R21AG040589, R21AG038835, P50AG005134, P50AG025688, P30AG062421)
- National Institute of Neurological Disorders and Stroke (F31NS079039, R01NS074874, R21NS067127, R01NS081555, R01NS071835)
- National Center for Research Resources (P51RR000165)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- protein aggregation, Alzheimer's disease, amyloid-beta, tau protein, amyloid plaques, neurofibrillary tangles, protein misfolding, prion-like propagation, neurodegenerative diseases, therapeutic target
- MeSH terms
- Animals, Humans, Neurofibrillary Tangles, tau Proteins, Protein Folding, Neurodegenerative Diseases, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review